Project Grant R01CA314164
Award Date 7/3/26
Completion Date 6/30/31
Dollars Obligated $627K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Austin, MN 55912, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $408,829 Project Grant to the Regents of the University of Minnesota, Office of Sponsored Projects Administration, under the Cancer Treatment Research program (CFDA 93.395) for the period May 1, 2026 through April 30, 2028. The award supports research into the therapeutic restoration of cholangiocyte primary cilia via microbiota-derived butyrate as a novel approach for treating cholangiocarcinoma (bile duct cancer). The...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $119,858 to the Regents of the University of Minnesota under the Cancer Biology Research program (CFDA 93.396) on August 7, 2025, for a project extending through July 31, 2030. This project grant supports fundamental research aimed at elucidating and overcoming T cell dysfunction in pancreatic ductal adenocarcinoma (PDA), a disease notoriously resistant to immunotherapy. The research program comprises three...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $406,325 to the University of Minnesota on May 7, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop CRISPRMAP-CYTOF, an innovative single-cell screening platform that combines pooled CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) perturbations with mass cytometry analysis. This collaborative effort between Dr. Xiaokang Lun's laboratory at the University of Minnesota and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Minnesota $141,016 under the Cancer Research Manpower program (CFDA 93.398) on December 1, 2025, with completion anticipated by June 30, 2027. This project grant funds structural and mechanistic research into APOBEC3A (A3A) and APOBEC3B (A3B) enzymes, which function as host defense mechanisms against viral infection while also contributing to cancer mutagenesis. The research addresses...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $573,262 through the Cancer Biology Research program (CFDA 93.396) to the Regents of the University of Minnesota to develop innovative autologous humanized patient-derived xenograft (PDX) models for preclinical testing of cancer immunotherapies. The award, effective April 17, 2026, through March 31, 2031, supports research to overcome current limitations in immunotherapy development by creating in vivo models that...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $309,761 to the Regents of the University of Minnesota under the Cancer Research Manpower program (CFDA 93.398) on May 1, 2026, for a project period extending through April 30, 2031. The award funds the development and delivery of an innovative training course on biomarker development and applications in cancer prevention research. The course combines structured didactic content with hands-on laboratory experience,...
- Federal Project Grant Award Summary The University of Minnesota's Office of Sponsored Projects Administration received a $395,973 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded September 5, 2025, with completion targeted for August 31, 2027. The project focuses on developing deazaflavin analog compounds as selective inhibitors of multidrug resistance protein 1 (MRP1) to enhance cancer chemotherapy efficacy. The research will...
- Federal Grant Award Summary The National Cancer Institute awarded $386,700 to the Regents of the University of Minnesota under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 7, 2025, for preclinical development and validation of targeted mass spectrometry assays for serous ovarian cancer diagnosis. The project, which runs through June 30, 2027, will deliver novel parallel reaction monitoring (PRM) assays capable of differentiating serous ovarian cancer patients from...
- Federal Grant Award Summary The National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded a $661,721 Project Grant to the University of California, San Diego, effective April 1, 2026, through March 31, 2031. This award supports systematic functional mapping and interrogation of oncogenic intrinsically disordered regions (IDRs) in cancer driver proteins. The research will utilize high-throughput functional screening technologies to perform domain and residue-level...
- Federal Project Grant Award Summary Mayo Clinic received a $161,400 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for the period August 1, 2025 through July 31, 2027. The award supports research to develop and validate innovative ferroptosis-based therapeutic approaches targeting cholangiocarcinoma (CCA), a highly lethal malignancy of the liver and biliary tract with a five-year survival rate below 10%. The...